k 2007

A new concept for modelling the number of cancer patients potentially treated in the Czech Republic

DUŠEK, Ladislav, Tomáš PAVLÍK, Eva GELNAROVÁ, Jan MUŽÍK, Jana KOPTÍKOVÁ et. al.

Basic information

Original name

A new concept for modelling the number of cancer patients potentially treated in the Czech Republic

Name in Czech

Modelování počtu potenciálně léčených onkologických pacientů v ČR

Name (in English)

A new concept for modelling the number of cancer patients potentially treated in the Czech Republic

Authors

Edition

TIES 2007, 2007

Other information

Language

Czech

Type of outcome

Prezentace na konferencích

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Medicine

ISBN

978-80-210-4333-6

Keywords in English

modelling; cancer prevalence; cancer survival; cancer incidence

Tags

Změněno: 30/6/2008 12:43, RNDr. Tomáš Pavlík, Ph.D.

Abstract

ORIG EN

V originále

The approach combines epidemiological trends in incidence and prevalence with demographic databases (used for estimates of relative X-yrs survival) and with cancer-specific mortality data that were applied to estimate the rate of dissemination relapses of the disease. The functionality and power of the model is well documented on Czech National Cancer Registry with more than 1,4 million of cases reported since 1977. Long-term history of the registry allows even 30-yrs relative survival estimates with mortality data separating death events due to cancer from the other reasons. Finally, summed numbers of patents that are probable to be treated in a given year are supported with reasonable confidence limits. All estimates are performed in age-specific format with respect to the clinical stage of the patients.

In English

The approach combines epidemiological trends in incidence and prevalence with demographic databases (used for estimates of relative X-yrs survival) and with cancer-specific mortality data that were applied to estimate the rate of dissemination relapses of the disease. The functionality and power of the model is well documented on Czech National Cancer Registry with more than 1,4 million of cases reported since 1977. Long-term history of the registry allows even 30-yrs relative survival estimates with mortality data separating death events due to cancer from the other reasons. Finally, summed numbers of patents that are probable to be treated in a given year are supported with reasonable confidence limits. All estimates are performed in age-specific format with respect to the clinical stage of the patients.